TEVA Stock Recent News
TEVA LATEST HEADLINES
Stanley Druckenmiller made a fortune working alongside billionaire George Soros. He ran his own hedge fund for years before closing it in 2010.
TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in reducing frequency, duration and severity of migraine attacks in patients with chronic and episodic migraine.1
TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy TEL AVIV, Israel and SHANGHAI , June 16, 2025 /PRNewswire/ -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
There's nothing more valuable on Wall Street than data, and investors rarely have to dig to find something that's pertinent to the U.S. economy, the stock market, or their specific portfolio holdings.
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Richard D. Francis - President, CEO & Director Conference Call Participants Matthew Michael Dellatorre - Goldman Sachs Group, Inc., Research Division Matthew Michael Dellatorre Okay.
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Jefferies Global Healthcare Conference June 4, 2025 9:20 AM ET Company Participants Christine Fox - Executive VP of U.S. Commercial Business Eric A. Hughes - Executive VP of Global R&D and Chief Medical Officer Conference Call Participants Dennis Ding - Unidentified Company Dennis Ding Good morning.
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced tender offers (the “Offers”) to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the series described in the table below (the “Notes”) upon the terms of, and subject to the conditions as set out in, the Offer to Purchase, dated May 19, 2025 (the “Offer to Purchase”). Capitalized terms used in this announcement but not otherwise defined shall have the meanings given to them in the Offer to Purchase.
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: